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Background: Effective chemotherapy rapidly reduces the spin–lattice relaxation of water protons (T1) in solid
tumours and this change (ΔT1) often precedes and strongly correlates with the eventual change in tumour volume
(TVol). To understand the biological nature of ΔT1, we have performed studies in vivo and ex vivo with the allosteric
mTOR inhibitor, everolimus.
Methods: Mice bearing RIF-1 tumours were studied by magnetic resonance imaging (MRI) to determine TVol and
T1, and MR spectroscopy (MRS) to determine levels of the proliferation marker choline and levels of lipid apoptosis
markers, prior to and 5 days (endpoint) after daily treatment with vehicle or everolimus (10 mg/kg). At the endpoint,
tumours were ablated and an entire section analysed for cellular and necrotic quantification and staining for the
proliferation antigen Ki67 and cleaved-caspase-3 as a measure of apoptosis. The number of blood-vessels (BV) was
evaluated by CD31 staining. Mice bearing B16/BL6 melanoma tumours were studied by MRI to determine T1 under
similar everolimus treatment. At the endpoint, cell bioluminescence of the tumours was measured ex vivo.
Results: Everolimus blocked RIF-1 tumour growth and significantly reduced tumour T1 and total choline (Cho)
levels, and increased polyunsaturated fatty-acids which are markers of apoptosis. Immunohistochemistry showed
that everolimus reduced the %Ki67+ cells but did not affect caspase-3 apoptosis, necrosis, BV-number or cell density.
The change in T1 (ΔT1) correlated strongly with the changes in TVol and Cho and %Ki67
+. In B16/BL6 tumours,
everolimus also decreased T1 and this correlated with cell bioluminescence; another marker of cell viability.
Receiver-operating-characteristic curves (ROC) for everolimus on RIF-1 tumours showed that ΔT1 had very high
levels of sensitivity and specificity (ROCAUC = 0.84) and this was confirmed for the cytotoxic patupilone in the same
tumour model (ROCAUC = 0.97).
Conclusion: These studies suggest that ΔT1 is not a measure of cell density but reflects the decreased number of
remaining viable and proliferating tumour cells due to perhaps cell and tissue destruction releasing proteins and/or
metals that cause T1 relaxation. ΔT1 is a highly sensitive and specific predictor of response. This MRI method
provides the opportunity to stratify a patient population during tumour therapy in the clinic.
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Biomarkers are crucial to the development of new drugs
and optimization of the existing options, by facilitating
selection of the population to treat, confirming proof-of-
concept and acting as early markers of tumour-response.
The latter can be provided in the clinic by non-invasive
functional imaging, for example positron emission tom-
ography (PET) measurements of 2′-deoxy-2′-[18 F]
fluoro-glucose (FDG) and 3′-deoxy-3′-[18 F]fluorothy-
midine (FLT), dynamic contrast-enhanced magnetic
resonance imaging for vascular parameters and diffusion-
weighted imaging for apoptosis [1,2]. However, they are
not always easy to implement, and furthermore may be in-
appropriate for the mechanism-of-action (MoA) of a par-
ticular drug and cannot always detect true responses to
the treatment [3-6]. We have recently described a rapid,
robust MRI-method, which detects the response of solid
tumours to drugs with different MoA in several different
experimental models [7]. The method quantifies the spin–
lattice relaxation of protons (T1) in tumours both rapidly
and accurately using an IR-TrueFISP method. Across sev-
eral models, the fractional change in tumour T1 (ΔT1) cor-
related with the percentage of cells positive for the antigen
Ki67 (a marker of cycling cells), but not with other
markers such as apoptosis, necrosis or blood volume, all
of which showed no consistent change with drug-
treatment [7]. Recently, a preclinical study in a neuro-
blastoma mouse model treated with three different
drugs showed a consistent decrease in T1 [8], and a clin-
ical study reported a small decrease in T1 in patients
with colorectal cancer metastasis undergoing bevacizu-
mab therapy [9].
To investigate further what ΔT1 reflects about the
tumour biology, we have compared ΔT1 with magnetic res-
onance spectroscopy (MRS) markers of proliferation and
apoptosis in vivo [10], as well as histology and immunohis-
tochemistry ex vivo following treatment with the allosteric
mTOR inhibitor, everolimus (Afinitor) in two different
murine tumour models, RIF-1 and B16/BL6. Everolimus
was selected for these studies because although the drug
has significant clinical activity in several different types of
cancer, there is currently no confirmed molecular marker
that can stratify the patient population [11]. Using the
RIF-1 model, we demonstrate that ΔT1 is a highly sensitive
and specific predictor of response to everolimus and also
the microtubule stabilizer patupilone. Collectively, these
data further suggest that incorporation of T1 measurements
in clinical trials should be an important aid to drug devel-
opment and optimization of existing drugs.
Methods
Tumour Models
All animal experiments were carried-out strictly according
to the local Swiss animal welfare regulations. The protocolwas approved by the local veterinary authorities (Kanto-
nales Veterinäramt Basel-Stadt, permit number 1974).
C3H/He female mice (20–25 g) and C57/BL6 mice (20 g)
were obtained from Charles River (France) and were accli-
matized to local conditions for at least one week prior to
experiments. Three experiments were performed in the
RIF-1 fibrosarcoma model in C3H/He mice, one expe-
riment was performed in the B16/BL6 melanoma model
in C57/BL6 mice. All animal experiments were performed
under isoflurane anesthesia, and every effort was made to
minimize suffering.
Tumour volume (TVol) and animal body-weight (BW)
measurements were made at least twice per week inclu-
ding just before treatment (baseline) and the endpoint.
TVol was determined using calipers to measure three or-
thogonal dimensions and applying the formula: l*h*w*π/6.
Murine RIF-1 fibrosarcoma
Freshly cultured RIF-1 tumour cells were injected sub-
cutaneously (5 × 106 in 50 μL phosphate-buffered saline)
in the upper thigh of anesthetized C3H/He mice, as pre-
viously described [12]. After 2 weeks, tumours were of
sufficient size (at least 200 mm3) for the studies and
were divided into two equal groups and treated daily
with compound or vehicle. Experiment 1: treatment with
everolimus (n = 7) compared to vehicle (n = 7), experi-
ment 2: treatment with everolimus (n = 8) compared to
vehicle (n = 8), experiment 3, previously published in [7]:
three different doses of patupilone (each group n = 8)
compared to vehicle (n = 8).
Murine B16/BL6 melanoma
Freshly cultured B16/BL6 tumour cells expressing the
enzyme luciferase were injected intra-dermally (5 x 104
in 1 μl) into the dorsal pinna of both ears of anesthetized
C57/BL6 mice as previously described [12,13]. These
black melanoma cells rapidly metastasize from the pri-
mary ear tumour to the regional lymph-nodes, in par-
ticular the neck. After 2 weeks, mice were divided into
two equal groups (n = 10) and treated daily with everoli-
mus (10 mg/kg p.o.) or vehicle for 6 days (experiment
4). MRI was performed on the metastasis in the cervical
lymph nodes on day 5. In one mouse in the vehicle
group there was no measurable lymph node metastasis.
Compounds/drugs and their application
All compounds utilized in this study were obtained from
the Novartis chemical department. The compounds and
their respective vehicles were prepared each day just
prior to administration to animals and the administra-
tion volume individually adjusted based upon animal
body weight. Everolimus (RAD001) was obtained as a
microemulsion and was freshly diluted in a vehicle of 5%
glucose and administered by oral gavage (p.o.) to mice
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(epothilone B, EPO906) was dissolved in polyethylene
glycol-300 (PEG-300) and then diluted with physiological
saline (0.9% w/v NaCl) to obtain a mixture of 30% (v/v)
PEG-300 and 70% (v/v) 0.9% saline. Treatment with ve-
hicle (PEG-300/saline) or patupilone (3, 5 or 6 mg/kg) was
once weekly using an i.v. bolus of 2–3 sec in the tail vein.Experimental design
Mice were divided into different treatment groups so
that each group had the same mean TVol, and magnetic
resonance (MR) measurements were made before treat-
ment (baseline) i.e. day 0 and at the endpoint. For eve-
rolimus, the endpoint was day 5, and for patupilone it
was day 7. T1 was measured in all four experiments.
MRS was performed in experiment 1 only. Biolumines-
cence was measured ex vivo in experiment 4 (see below).
At the end of everolimus-experiment 1, animals were
sacrificed by CO2 inhalation, the tumours ablated and pre-
pared for histology and immunohistochemistry (IHC) as
previously described [7].Magnetic Resonance in vivo
Animals were anaesthetised using 1.5% isoflurane (Abbott,
Cham, Switzerland) in a 1:1 mixture of O2/N2 and placed
on an electrically warmed pad for canulation of one lateral
tail-vein as previously described [7]. MRI experiments were
performed on a Bruker DBX 47/30 or Avance 2 spectrom-
eter (Bruker Biospin, Ettlingen, Germany) at 4.7 T equipped
with a self-shielded 12 cm bore gradient system.Quantitative T1 imaging
The spin–lattice relaxation of protons (T1) was mea-
sured with an inversion recovery (IR) TrueFISP (true
fast imaging with steady state precession sequence,
[14]) imaging sequence as previously described [7].
The basic sequence was a series of 16 TrueFISP images
acquired at a time interval, TI, following a global 180°
inversion pulse (TI = 210 ms to 5960 ms in 324 ms in-
crements). Each TrueFISP image (one slice containing
the central part of the tumour) was acquired with a flip
angle α of 30°, a matrix size of 128 × 96, a field-of-view
of 30 × 22.5 mm2, a slice thickness of 2 mm, an echo
time (TE) of 1.7 ms, and a repetition time (TR) of
3.4 ms. Pixelwise T1 calculation was done using the
method described in [15]. A region of interest (ROI)
comprising the entire tumor was drawn manually on
the resulting T1 map and the mean T1 of the central
tumour slice was calculated in this ROI. MR image
analysis was performed off-line with in-house written
software based on IDL 6.0 programming environment
(Research Systems Inc., Boulder, CO, USA).1H-MR spectroscopy
Localized shimming with FASTMAP method was per-
formed on a 2.5 mm3 voxel to obtain line widths
of <20 Hz. Point resolved spectroscopy (PRESS) experi-
ments at the same voxel position (voxel size = 8 mm3, TE =
20 msec, TR = 1500 msec, SW= 4000 Hz, TD= 2048, with
external volume suppression) were performed. One
spectrum was acquired with water suppression (400 av-
erages) and one spectrum without water suppression
(1 average). The total time for MRS was 10–12 min for
each mouse. The water signal (one peak) of the non-
suppressed spectrum was used as an internal reference
for relative quantification of metabolites using the me-
tabolite to H2O ratio (Cho/H2O for choline, etc.). Peaks
in the water-suppressed spectrum were identified by
their chemical shifts, so total choline (Cho) was at 3.2 ppm,
CH3-lipids at 0.9 ppm, CH2-lipids at 1.3 ppm, creatine at
3.0 ppm, and polyunsaturated fatty-acids (PUFA) at
5.3 ppm and very weakly at 2.8 ppm; however the latter
peak was not used for any calculations.
Histology and immunohistochemistry
A tumour slice of 3–4 mm thickness was cut from the
largest circumference of the tumour, immersion-fixed in
4% (w/v) phosphate-buffered formalin (pH 7.4; J.T.
Baker, Medite, Service AG, Dietikon, Switzerland) at
4°C for 24 hours and processed into paraffin as previously
described [4]. IHC was performed on paraffin sections of
3 μm using the following antibodies for detection of (i)
cleaved Caspase-3 (rabbit polyclonal antibody #9661, Cell
Signaling, Danvers, MA, USA) (ii) Ki67 (rat monoclonal anti-
body, clone TEC3, #M7249, DAKO, Glostrup, Denmark)
and (iii) CD31 (rabbit polyclonal antibody, #E11114, Spring
Biosciences, Pleasanton, CA, USA).
Image acquisition and analysis of histological slices
For quantification, the entire section was scanned using
the MiraxScan system (Carl Zeiss AG, Jena, Germany).
The absolute size of viable, necrotic and complete tissue
areas was measured on the full scans using MiraxViewer
software (Carl Zeiss AG, Jena, Germany). Quantification
of Ki67 positive and negative nuclei in the complete vi-
able areas was performed in a fully automated manner
with TissueMap software at Definiens AG, Munich,
Germany. Results were summarized as the total area,
percentage-viable and percentage-necrotic area, total
number of nuclei and the cell density (number of nuclei
per mm2) in both the viable and total (including there-
fore necrotic) areas. Cleaved caspase-3 positive particles
were quantified as positive pixels per total pixels in a
semi-automated fashion with the AnalySIS® FIVE soft-
ware (OlympusSIS, Münster, Germany) on six images
(346.7 x 260 μm2 each) per section excluding necrotic
areas and border zones of necrotic areas. CD31 stained
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scanner (Aperio, Vista, CA, USA) and vessels were
quantified with the Aperio ImageScope software, using
the Microvessel Analysis v1 Algorithm.
Bioluminescence
Because of the black pigmentation of the C57/BL6 mice,
bioluminescence (BioL) could not adequately be measured
in vivo and therefore was determined ex vivo as follows.
After 6 days, the cervical lymph-nodes were removed and
weighed and then iced. Individual lymph-nodes were ho-
mogenized at 4˚C with 1 mL cold phosphate-buffered sa-
line (without Ca2+ and Mg2+), rinsed in the same buffer,
and 200 μl triplicates placed in a 96-well plate with 50 μl
D-luciferin (1 mg/mL). BioL was measured at an emission
wavelength of 560 nm using the imaging chamber of the
IVIS™ system (Caliper Life Sciences Inc, Hopkinton, MA,
USA) for 1 min at room temperature.
Data analysis
Results are presented as mean ± SEM except where stated
and all available data are shown. The T/C ratio is com-
monly used to quantify tumour growth inhibition, where
T and C represent the means of the relative tumour vol-
umes (tumour volume divided by its initial volume) of the
treatment and control mice, respectively [16]. Longitu-
dinal changes, such as in tumour volume (ΔTVol) or in
T1 (ΔT1), were expressed as change between endpoint and
baseline divided by value at baseline (fractional change
in %). The T/C ratio was calculated for all parameters. For
parameters measured at one time point only (such as
histological read-outs), T/C was calculated as ratio of
means of treatment and control mice, respectively. Differ-
ences between groups were analysed using a 2-tailed t-test.
For the in vivo biomarker analyses which involved longitu-
dinal analyses in the same animals, differences were ana-
lysed by a) 2-way repeated measures ANOVA and b) t-test
at the endpoint; the latter method is therefore associated
with the respective T/C. The different dose groups in
experiment 3 were tested with 1-way ANOVA vs. control
group. Quantification of the linear-relationship between
the various parameters measured in vivo and ex vivo were
analysed by Pearson’s correlation to provide the correl-
ation coefficient (r) and the significance (p). Application of
the non-parametric Spearman’s correlation did not affect
the results except in one case (see Results). To facilitate
comparison of PUFA levels which were not always de-
tectable, a 2-sided Fisher’s exact test was also used. For
all tests, the level of significance was set at p < 0.05
(two-tailed) where *p < 0.05, **p < 0.01, ***p < 0.001 ver-
sus vehicle.
To determine the sensitivity and specificity of a change in
the imaging marker T1 as a marker of tumour response to
treatment, receiver-operator curves (ROC) were generated[17,18] using Graphpad Prism (GraphPad Software, La
Jolla, CA, USA) considering mice treated with the drugs
everolimus (experiment 1 and 2) or patupilone (experi-
ment 3). Briefly, responders (R) to drug-treatment were
defined as showing no change or regression, in TVol,
defined as ΔTVol ≤ 10%, while all others were consid-
ered non-responders (NR). Each of these tumours was
then classified as R or NR by the ΔT1 at different
discrete cut-offs to generate at each ΔT1 value a table of
positive and negative predictions for determination of
specificity and sensitivity at each value. The plot of 1-
specificity versus sensitivity generated the ROC curve
and the area under this curve (AUC) was quantified by
the trapezoidal method.
Results
Effects of everolimus on MRI and MRS biomarkers in RIF-1
tumours in vivo
Murine RIF-1 tumours grew rapidly having a 2.5-fold in-
crease in tumour volume after just 5 days, but daily
treatment with everolimus (10 mg/kg p.o.) strongly
inhibited tumour growth causing essentially stable dis-
ease at the 5 day endpoint with a T/C of 0.05 (Table 1).
Both groups had a significant difference in TVol at base-
line (slightly larger TVol in the treatment group), but
this did not have an effect on the results, as can be seen
in Table 1. Quantification of tumour T1 by MRI at base-
line gave a mean ± SD of 2301 ± 100 msec (both groups,
n = 14) which showed no significant change in vehicle-
treated mice, but was reduced in 7/7 mice treated with
everolimus providing a small but highly significant mean
decrease of 10 ± 2% after 5 days treatment (Figure 1,
Table 1).
1H-MRS on the same tumours at the same time-points
was also performed to provide signals for total choline,
creatine, as well as polyunsaturated lipids (PUFA) and
saturated (CH2 and CH3) lipids (Figure 2A). The strong
water signal (unsuppressed) was used to provide quanti-
tative information as ratios (see Methods). This data
showed that creatine and saturated lipids did not change
in either treated-group (Table 1). However, total choline
(Cho) in most cases (5/7) decreased in everolimus-
treated tumours, with a mean change in choline ΔCho/
H2O of 27 ± 15% (statistically significant only in ANOVA,
not in t-test; Figure 2B,C). The PUFA peaks were broad
and of low intensity (Figure 2A) and were only detectable
at baseline in 1/7 tumours for each group. However, after
5 days treatment they were more prevalent, permitting
quantification in 2/7 vehicle-treated and 5/7 everolimus-
treated tumours which showed a T/C of 2.2 (Table 1). This
data was obviously rather variable and scarce due to the
limit-of-detection by MRS and there was no significant
difference between the two groups although a two-way
repeated-measures ANOVA (as used for T1 and Cho)
Table 1 Summary of RIF-1 measurements in vivo and ex vivo
Parameter Vehicle Everolimus T/C
Day 0 Day 5 Day 0 Day 5
TVol (mm3) 447 ± 75 1118 ± 150 706 ± 85 736 ± 100 0.05***
T1 (msec) 2266 ± 46 2265 ± 30 2335 ± 23 2090 ± 45 0.89**
choline/H2O [a.u.] 2.72 ± 0.18 2.72 ± 0.2 2.6 ± 0.12 1.82 ± 0.32 0.73
CH2/H2O [a.u.] 6.44 ± 0.85 7.3 ± 1.17 6.89 ± 0.35 11.0 ± 1.5 1.3
CH3/H2O [a.u.] 2.56 ± 0.43 2.86 ± 1.74 3.06 ± 0.34 4.87 ± 0.72 1.2
PUFA/H2O [a.u.] 0.1 ± 0.1 0.37 ± 0.24 0.25 ± 0.25 0.8 ± 0.39 2.2
creatine/H2O [a.u.] 1.27 ± 0.15 1.14 ± 0.05 1.07 ± 0.06 0.89 ± 0.09 0.9
total area (mm2) - 65.8 ± 10.0 - 43.6 ± 5.6 0.66
viable area (mm2) - 52.1 ± 9.4 - 33.1 ± 4.7 0.64
%necrosis - 21.5 ± 6.1 - 24.9 ± 3.3 1.16
total cells (thousand) - 489 ± 82 - 328 ± 48 0.67
cells/viable mm2 - 9671 ± 454 - 9923 ± 562 1.03
%Csp+ area - 0.39 ± 0.07 - 0.27 ± 0.02 0.7
BV per mm2 - 728 ± 159 - 768 ± 37 1.06
%Ki67+ cells - 44.6 ± 2.5 - 26.5 ± 1.0 0.59***
Ki67+cells/mm2 - 4274 ± 205 - 2614 ± 141 0.61***
Ki67- cells/mm2 - 5396 ± 457 - 7309 ± 462 1.35*
C3H mice bearing RIF-1 tumours were treated with everolimus (10 mg/kg/day, n = 7) or vehicle (n = 7) for 5 days prior to sacrifice. Tumour volume, T1 and the
various MRS parameters were quantified prior to treatment (day 0) and after 5 days treatment. Animals were then culled and the tumours ablated and prepared
for immunohistochemistry as described in Methods. After immunostaining for Ki67 and cleaved caspase-3, the entire tumour sections were scanned to provide
viable and necrotic areas in mm2. The number of cells and the number and percentage staining for Ki67 and caspase-3 is shown only for the viable area but
essentially identical results were obtained if the entire area was used. Blood vessels (BV) were quantified from CD31 stained slices. All results show the mean ± SEM for
each tumour, significant changes are indicated by emboldened numbers where *p < 0.05, **p < 0.01, ***p < 0.001 comparing the two treatment group means
(2-tailed t-test).










































Figure 1 Everolimus decreases the T1 of RIF-1 tumours. C3H mice bearing RIF-1 tumours were treated with everolimus (10 mg/kg/day) or
vehicle for 5 days and the spin–lattice relaxation of protons (T1) in tumours was measured on day 0 and at the endpoint day 5. Results show
the individual values for each tumour, n = 7 per treatment group (A) and the mean ± SEM fractional change ΔT1 for each treatment (B), where
*p < 0.05, **p < 0.01, ***p < 0.001 as shown. Panel C & D show an MRI-derived T1 map from a representative RIF-1 tumour (arrow) before (C) and
after (D) treatment with everolimus.
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Figure 2 Everolimus decreases the Cho/H2O ratio of RIF-1 tumours. C3H mice bearing RIF-1 tumours were treated with everolimus (10 mg/kg/day)
or vehicle for 5 days and the ratio of total choline to (unsuppressed) water (Cho/H2O) in tumours was measured on day 0 and at the endpoint
day 5. Panel A shows a 1H-MRS spectrum from a representative RIF-1 tumour before and after treatment with everolimus. Graphs show the
individual values for each tumour, n = 7 per treatment group (B) and the mean ± SEM fractional change ΔCho/H2O for each treatment (C), where
*p < 0.05 as shown.
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0.007), a parameter that has also been associated with
apoptosis [10].
Ex vivo analyses of everolimus on RIF-1 tumours
At the endpoint, the ablated tumours were prepared for
histology. Since everolimus inhibited tumour growth,
there was of course a reduction in the total and viable
area and consequently a reduction in the total cell num-
ber examined by IHC comparing everolimus-treated to
vehicle-treated mice (Table 1, Figure 3), although these
did not quite reach significance (p = 0.1). The cell density
(cells per mm2) in the viable (or total) area and the %-ne-
crosis was the same in each group (Table 1). The number
of cells positive for the proliferation marker Ki67 was re-
latively high in vehicle-treated mice (45 ± 3%) and evero-
limus caused a clear and highly significant decrease in
the total number and %Ki67+ cells to 27 ± 1% (Table 1;
Figure 3, first and second row). Correspondingly, there
was a significant increase in the number of Ki67- cells. In
contrast, there was a very low level of apoptosis as mea-
sured by caspase-3 staining in these tumours (<1%) and
this was not affected by everolimus treatment (Table 1;
Figure 3, third row). The number of blood-vessels (BV)
per slice was rather variable, particularly in the vehicle-
group, and a comparison of the blood-vessel densitybetween treatment groups showed no effect from everoli-
mus (Table 1; Figure 3, last row CD31).
Relationships between RIF-1 biomarkers and tumour
response
As previously observed for several different experimental
models and drugs, including everolimus [7], the change in
T1 (ΔT1) was highly significantly (p = 0.0032) positively cor-
related with the change in RIF-1 tumour volume (ΔTVol),
see Figure 4A, but there was no significant correlation be-
tween ΔCho/H2O and ΔTVol. Correlation of ΔT1 and
ΔCho/H2O reached significance (r = 0.58, p = 0.028), see
Figure 4B, although not when a Spearman correlation was
applied (r = 0.43, p = 0.13). ΔT1 showed a significant posi-
tive correlation with the %Ki67+ cells (Figure 4C), a similar
level of correlation existed between %Ki67+ and ΔCho/H2O
(r = 0.56, p = 0.036); and of course negative correlation with
the %Ki67- cells (graphs not shown). There was no sig-
nificant relationship between basal T1 value and ΔTVol
in keeping with previous observations in many different
preclinical models [7] that basal T1 cannot predict re-
sponse. The final T1 or ΔT1 was unrelated to cell dens-
ity, or indeed the total number of cells, with flat lines of
correlation and wide scatter (results not shown). Thus,
ΔT1 was unrelated at the endpoint to cell density or the
extracellular space but was related to the remaining




















Figure 3 Immunohistochemistry in RIF-1 tumours after everolimus or vehicle treatment. C3H mice bearing RIF-1 tumours were treated
with vehicle (A, left column) or everolimus at 10 mg/kg/day (B, right column) for 5 days prior to sacrifice (n = 7 per group). Tumours were ablated
and prepared for immunohistochemistry as described in Methods. The entire sections were scanned. Ki67-stained slices of one representative
tumour from each treatment (scalebar = 1 mm) are shown in row 1. Viable tumor tissue is outlined in red and necrosis regions are marked with
asterisks. Percentage of Ki67-positive cells was 46% and 26% and the total tumour area was 43.9 mm2 (8% necrosis) and 22.4 mm2 (19% necrosis)
for the vehicle-treated and everolimus-treated mice, respectively. Magnified sections stained for Ki67 (scalebar = 50 μm), cleaved caspase-3 (CASP3,
scalebar = 25 μm), and CD31 (scalebar = 25 μm) are shown below in row 2, 3, and 4, respectively. There was no difference between the groups in
apoptosis (CASP-3 staining) and blood-vessel density (CD31 staining).
Figure 4 Inter-relationships of biomarkers following everolimus or vehicle treatment of RIF-1 tumours. Graphs A-C show Pearson
correlations with the associated r and p values between the fractional change in T1 (ΔT1 ) and the fractional change in tumour volume (ΔTVol),
the fractional change in total choline (ΔCho/H2O), and percentage of Ki67 positive cells, respectively, after 5 days of everolimus or vehicle
treatment (n = 7 per group) of C3H mice bearing RIF-1 tumours.
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to the number of non-proliferating cells). PUFA levels,
which also tended to change with treatment could not
be formally correlated since the data was categorical,
but a Fisher’s exact test showed a significant association
between Cho and PUFA (p = 0.02) i.e. proliferation de-
creased as apoptosis increased.
Sensitivity and specificity of ΔT1 as a response biomarker
in RIF-1 tumours
Correlations and linear regression provide indications of
whether a biomarker could be used to predict response,
but a receiver operating characteristic curve (ROC) can
be more definitive in terms of the specificity and sensi-
tivity of the marker. To generate such a curve for evero-
limus, data from experiments 1 and 2 was pooled from
RIF-1 tumours (Figure 5A). The left panel shows the
ΔTVol for mice treated with vehicle or everolimus and
the right panel the ΔT1 in those tumours from day 0 to
day 5 (n = 15 vehicle, n = 13 everolimus; in the everoli-
mus group of experiment 2 one mouse died before end-
point and T1 measurement failed in another mouse).
Responders to everolimus treatment were defined as
showing a maximum change in ΔTVol of +10% (stable
disease or regression), so giving 5R and 8NR and provi-
ding the ‘gold-standard’. Each of these 13 tumours was
then classified as a R or NR by the ΔT1 using different
discrete cut-offs ranging from −16.5% to −2.5% to gener-
ate at each ΔT1 value a table of positive and negative
predictions for determination of specificity and sensiti-
vity at each value, see for example Table 2A. The plot of
1-specificity versus sensitivity generated the ROC curve
and the area under this curve (AUC) was quantified gi-
ving a value of 0.84 which is considered to be very good
predictive ability [17].
The same approach was used to analyse data already
published [7] from the cytotoxic patupilone on the same
RIF-1 tumour model. In this case, a dose–response was
used (Figure 5B, left panel) and R and NR identified in
the same way giving 7R and 13NR (from the 20 tu-
mours). The right panel (Figure 5B) shows the ΔT1 in
those tumours from day 0 to day 7 (n = 6-8 per dose).
Using once more discrete ΔT1 values from −24% to
8.5% a table of positive and negative predictions was
generated (see for example Table 2B) and the ROC plot-
ted (Figure 5B). The AUC of this plot was 0.97 confirming
outstanding predictive ability for ΔT1 in the RIF-1 model.
Relationship between bioluminescence and T1 in
B16/BL6 tumours
Everolimus inhibited growth of B16/BL6 lymph-node
metastases after 6 days daily treatment leading to a T/C
ratio for the weight of the dissected metastases of T/
Cweight = 0.60 and this was associated with a highlysignificant decrease in the T1 of the metastases of 19 ±
3% (Figure 6A,B). T1 measurement failed in one mouse
treated with vehicle and in two mice treated with evero-
limus resulting in n = 8 ΔT1 values in each group. Bio-
luminescence from these lymph-nodes measured ex vivo
was also significantly decreased (Figure 6C) and this cor-
related significantly with the ΔT1 (Figure 6D). Since the
enzyme luciferase is only located within the melanoma
cells, the bioluminescence should only reflect the viable
tumour cells which supports the notion that a change in
T1 is an indirect measurement of the viable and/or pro-
liferating cell fraction.
Discussion
We have previously shown that a small but highly sig-
nificant decrease in the mean spin–lattice relaxation of
protons (T1) of experimental tumours induced by vari-
ous different types of chemotherapy is strongly corre-
lated with the change in tumour volume and also the
immunohistochemical proliferation marker Ki67 [7].
Furthermore, in the RIF-1 model the antimetabolite 5FU
also decreased levels of the proliferation marker choline
and this too was correlated with the change in T1 (ΔT1).
The data presented here on RIF-1 and B16/BL6 tumours
confirm these observations for the allosteric mTOR in-
hibitor everolimus, providing further evidence that ΔT1
reflects the number of remaining proliferating tumour
cells following successful chemotherapy. The greater the
decrease in T1, the lower the percentage of proliferating
cells after therapy. In the previous report, a sample area
(10%) of an ex vivo tumour slice was examined histologi-
cally, and thus, true cell density and also therefore the
overall extracellular space could not be assessed either.
In two models, using the cytotoxic patupilone on murine
RIF-1 and rat mammary BN472, there were trends for
cell-density to decrease by approx. 10% but neither
reached significance [7]. In this report, we have made a
detailed histological study of the effect of everolimus on
RIF-1 tumours grown s.c. in murine C3H mice.
RIF-1 cells are sensitive to everolimus with an IC50
in vitro of 2.6 ± 1.6 nM (insensitive cells have an IC50 >
1 μM, see references [19,20]), but this is still not as sen-
sitive as the endothelial cells which have IC50 <1 nM,
which likely explains the fact that everolimus has anti-
tumour cell as well as anti-angiogenic properties [19].
Daily treatment of mice bearing RIF-1 tumours caused
tumour stasis, and consistent with this, histology at the
endpoint of 5 days showed a decrease in total tumour
area and a proportional decrease in the viable area of
approx. 35% compared to vehicle (both not significant,
p < 0.1). However, the total number of cells showed a
similar trend for a decrease in proportion (p < 0.1) and
thus the overall cell density in the viable areas was un-
changed. Since necrosis was also not affected by everolimus
AB
Figure 5 (See legend on next page.)
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Figure 5 Sensitivity and specificity of ΔT1 for everolimus and patupilone chemotherapy in the RIF-1 tumour model. A. C3H mice bearing
RIF-1 tumours were treated with everolimus (10 mg/kg/day) or vehicle for 5 days and TVol and the spin–lattice relaxation of protons (T1) in
tumours was measured on day 0 and at the endpoint day 5 (n = 15 per group on day 0). In the everolimus group, one mouse died before endpoint
and T1 measurement failed in another mouse on day 5. Results show the change in TVol (ΔTVol) (left panel) and the fractional change in T1
(ΔT1) (right panel) for each treatment on day 5, where **p < 0.01, ***p < 0.001 as shown. The ROC plots 1-specificity versus sensitivity for
tumours treated with everolimus only and has an AUC = 0.84; the dashed line is the line of equivalence where the AUC = 0.5. B. C3H mice
bearing RIF-1 tumours were treated with patupilone (3, 5 or 6 mg/kg i.v. bolus once) or vehicle and TVol and T1 in tumours was measured on
day 0 and at the endpoint day 7 (n = 8 per group). In some mice, T1 could not always be determined and thus there were only n = 6 or 7 per
group for analysis. Results show the ΔTVol (left panel) and the ΔT1 (right panel) for each treatment on day 7 where ***p < 0.001 as shown. The
ROC plots 1-specificity versus sensitivity for tumours treated with different doses of patupilone and has an AUC = 0.97; the dashed line is the line
of equivalence where the AUC = 0.5.
Table 2 T1 sensitivity and specificity tables for changes in
RIF-1 tumour volume following everolimus or patupilone
treatment
A. Everolimus: using a ΔT1 of −8%
ΔTVol
ΔT1 Positive Negative Total
Positive 5 3 8
Negative 0 5 5
Total 5 8 13
B. Patupilone: using a ΔT1 of −8%.
ΔTVol
ΔT1 Positive Negative Total
Positive 7 3 10
Negative 0 10 10
Total 7 13 20
A. Everolimus: The prevalence (total positive/all) = 0.38. The sensitivity =1.0
and the 1- specificity = 0.38, giving a positive prediction value of 0.63 and a
negative prediction value of 1.0 at this ΔT1 cut-off of −8%.
B. Patupilone: The prevalence (total positive/all) = 0.35. The sensitivity =1.0 and
the 1- specificity = 0.23, giving a positive prediction value of 0.70 and a nega-
tive prediction value of 1.0 at this ΔT1 cut-off of −8%.
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cell density and the extracellular space were unaffected.
Many previous experiments in vitro and using human
tumour xenografts in vivo have shown that T1 is sensitive
to a) the amount of water in the extracellular space (but
not intracellular) and b) the amount of protein in the water
[21-25]. It is well recognised that inhibition of mTOR (the
molecular target of everolimus) causes a decrease in cell
size [26], because cell cycle progression is blocked at G1
thus inhibiting protein synthesis and cell growth. Conse-
quently, cell density might not change, but the extracellular
space could increase. Unfortunately we could not measure
the average cell size because defining where one cell ends
and another begins is difficult and there was no automatic
programme for such an approach. But in any case, an in-
crease in extracellular space would lead to an increase ra-
ther than a decrease in T1 [21-25], suggesting that if cell
size changes occurred they could not explain the T1 de-
crease that we have always observed following successful
chemotherapy with many different agents [7]. This suggests
to us, that tumour cell and vascular destruction leads to the
release of proteins and also paramagnetic ions into the
extracellular space which causes the decrease in T1; an ef-
fect which has been shown in vitro [22]. However, everoli-
mus did not cause a decrease in the blood vessel density, as
has been seen in several other tumour models [20,27-29],
although this does not rule out an effect on the functional
vasculature (previously measured as low in RIF-1 tumours
[30]) and/or that early vascular changes had normalised by
day 5. Also in this model, there was no clear evidence of in-
creased tumour cell kill since caspase-3 levels were un-
affected, although there did appear to be a strong trend for
an increase in the PUFAs of everolimus-treated tumours
which has been associated with apoptosis in other experi-
mental models [10].
Immunohistochemistry (IHC) showed that approx.
half of vehicle-treated RIF-1 tumour cells were positive
for the nuclear antigen Ki67. Ki67 is considered to be a
proliferation marker since it is expressed in all cycling
cells (G1, S and G2M) but not therefore in cells in G0,
and is a convenient IHC tool in the clinic for assessing
tumour growth and response [31,32]. Given that theeffect of mTOR inhibition is to block G1, it was not sur-
prising that everolimus caused a marked decrease in the
%Ki67+ cells whether expressed as total number or dens-
ity and there was a proportional increase in the cells
negative for Ki67. Everolimus also decreased levels of
total choline (Cho) in RIF-1 tumours, which is another
marker of viable and proliferating cells, in this case
reflecting membrane turnover. Cho tends to be higher in
tumour than normal tissue [33] and successful chemo-
therapy has also been shown to decrease in Cho in both
experimental models [7,8,10] and the clinic [34,35]. In
the RIF-1 tumours, these proliferation markers correlated
significantly with each other as well as with the ΔT1, sup-
porting the notion that ΔT1 is a surrogate of the re-
maining number of proliferating cells in a tumour after
therapy even though our histological analysis suggests
that it cannot be measuring cell number or density dir-
ectly. Support for this hypothesis came from the B16/
BL6 model treated with everolimus where again the
Figure 6 Everolimus decreases the T1 and bioluminescence of cervical B16/BL6 melanoma metastases. C57/BL6 mice bearing B16/BL6
melanomas were treated with everolimus (10 mg/kg/day) or vehicle for 6 days and the spin–lattice relaxation of protons (T1) in tumours was measured on
day 0 and at the endpoint day 6. Lymph-nodes were removed and extracted for measurement of bioluminescence (BioL) as described in Methods. Results
show the mean ± SEM, and the individual T1 values (A) and bioluminescence (C), the fractional change in T1 (ΔT1) for the treatments (B), and the Pearson
correlations (with the associated r and p values) between BioL and ΔT1 (D), where **p < 0.01, ***p < 0.001 as shown.
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tumour cell number, was correlated to the ΔT1.
It is worth repeating that we have found that six diffe-
rent types of chemotherapy including anti-metabolites,
inhibitors of mTOR, microtubules, VEGF-R, PI3K and
HSP90 [7] [and unpublished] in several different tumour-
types implanted in both mouse and rat hosts, all showed a
decrease in T1 in response to successful chemotherapy i.e.
characterized by a significant change in TVol in compari-
son to vehicle-treated tumours. Furthermore, where a
tumour was resistant to that particular type of chemother-
apy (paclitaxel and patupilone), there was no change in T1
[7]. This suggests that ΔT1 is a generic marker of tumour
response, because, as discussed above, it reflects overall
tumour destruction. But, what is the level of sensitivity
and specificity i.e. how useful could such a method be in
the clinic? To answer this question, we used receiver-
operating-characteristic curves (ROC) to analyse two dif-
ferent models in which mice bearing RIF-1 tumours were
treated with either a single dose of everolimus or three dif-
ferent doses of patupilone. In both cases, the ROCs had a
large area-under-the-curve (AUC) of 0.84 and 0.97 which
is considered of very good to outstanding predictive ability
[17]. Consider for comparison, IHC markers of the mTOR
pathway to predict everolimus activity in vitro using cell
lines in which ROC-AUCs of 0.86-0.88 were determined[20]; also excellent predictive activity but no better or
even lower than that we have shown here. Indeed, with
our data, if a cut-off of an 8% decrease were selected
(i.e. ΔT1 = −8%), then the sensitivity to both drugs would
be perfect in this model at 1.0 i.e. providing a negative
predictive value of 100%. In other words, after two MRI-
scans one could completely eliminate from the study any
tumours with a T1 decrease smaller than 8% since these
should not benefit from further treatment.Conclusion
T1 showed a decrease in response to successful chemother-
apy in several tumour models using various drugs. Analysis
of histological and bioluminescence data from tumours
treated with everolimus indicate that ΔT1 is a generic
marker of tumour response reflecting overall tumour de-
struction and the decreased number of proliferating cells.
The excellent negative predictive value of ΔT1 suggests
that the method should be tested in the clinic, for ex-
ample wherever MRI is being used anyway to determine
tumour size. Potentially, it provides the opportunity to
stratify a patient population after the first cycle of treat-
ment to increase the effective response-rate as well as to
save resources by avoiding treatment of patients who are
unlikely to respond.
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